Skye Bioscience Inc. (09R0)
XMUN 
Summary
09R0 Chart
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions
SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it was selected to present new nimacimab data in its expanded preclinical model at the upcoming American Diabetes Association's (ADA) 85th Scientific Sessions. Skye will present in multiple forums at the ADA conference, which is being held June 20th – 23rd, 2025, at the McCormick Place Convention Center in Chicago, Illinois.
Skye Bioscience to Participate in Upcoming Investment Conferences
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences:
Arecor partners with Skye Bioscience to improve formulation of obesity drug
Arecor Therapeutics PLC (AIM:AREC) has entered a development partnership with Skye Bioscience Inc (NASDAQ:SKYE), a US-based biotechnology group, to create a more concentrated formulation of an experimental obesity treatment, as drugmakers vie for a share of the fast-growing weight-loss market. The Cambridge-based company will use its proprietary Arestat technology to reformulate nimacimab, a monoclonal antibody developed by Skye that targets the CB1 receptor.
Skye Bioscience Inc. Dividends
Skye Bioscience Inc. Earnings
| 8 May 2025 Date | | - Cons. EPS | - EPS |
| 19 Mar 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2024 Date | | - Cons. EPS | - EPS |
| 22 Mar 2024 Date | | - Cons. EPS | - EPS |
| 14 Nov 2023 Date | | - Cons. EPS | - EPS |
| 8 May 2025 Date | | - Cons. EPS | - EPS |
| 19 Mar 2025 Date | | - Cons. EPS | - EPS |
| 31 Mar 2024 Date | | - Cons. EPS | - EPS |
| 22 Mar 2024 Date | | - Cons. EPS | - EPS |
| 14 Nov 2023 Date | | - Cons. EPS | - EPS |
Skye Bioscience Inc. (09R0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Skye Bioscience Inc. ever had a stock split?
Skye Bioscience Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Punit S. Dhillon B.A. CEO | XMUN Exchange | US83086J2006 ISIN |
| US Country | 16 Employees | - Last Dividend | 8 Sep 2023 Last Split | 2 Apr 2015 IPO Date |
Overview
Skye Bioscience, Inc. is a clinical stage biopharmaceutical company engaged in the discovery, development, and potential commercialization of therapeutic drugs aimed at modulating the endocannabinoid system. With a strategic focus on generating transformative treatments, Skye Bioscience endeavors to address unmet medical needs across various domains. Originally known as Emerald Bioscience, Inc., the company underwent a name change in January 2021 to better align with its expanded vision and strategic goals. Skye Bioscience has established its headquarters in San Diego, California, leveraging the region's rich biotechnological ecosystem to advance its research and development efforts.
Products and Services
- Nimacimab
As Skye Bioscience's lead clinical program, nimacimab represents a pioneering approach in targeting the endocannabinoid system. Specifically designed as a peripherally-restricted negative allosteric modulating antibody, nimacimab focuses on the human cannabinoid receptor 1 (CB1). The therapeutic intent of targeting CB1 receptors, primarily involved in metabolic processes, positions nimacimab as a potential treatment for metabolic disorders, including obesity. Currently undergoing Phase II clinical trials, nimacimab is administered as a subcutaneous injection, reflecting Skye Bioscience's commitment to innovative and patient-friendly therapeutic solutions.
- SBI-100 Ophthalmic Emulsion
Expanding its portfolio into ophthalmology, Skye Bioscience is developing the SBI-100 Ophthalmic Emulsion, a CB1 agonist aimed at treating glaucoma and ocular hypertension. This novel formulation is in Phase II clinical trials, underscoring the company's dedication to leveraging the therapeutic potential of the endocannabinoid system across a spectrum of diseases. The SBI-100 Ophthalmic Emulsion represents a significant stride towards offering new treatment options for patients with eye conditions that are often challenging to manage effectively.
- Collaborative Development Efforts
In its pursuit of broadening the therapeutic applications of its research, Skye Bioscience has entered into a licensing agreement with Tautomer Bioscience, (Pty) Limited. This partnership focuses on the development and commercialization of SBI-100. Additionally, a collaborative research agreement with VivaCell Biotechnology Espana, S.L.U is in place for the research and development of SBI-200, as well as the provision of preclinical development services for novel derivatives. These collaborations highlight Skye Bioscience's strategy of leveraging partnerships to accelerate the development of innovative therapies.
Contact Information
